Mistletoe therapy, derived from the European plant Viscum album, is gaining recognition as a supportive treatment in oncology. Used for decades in integrative medicine, its mechanism of action involves both immune system stimulation and direct anti-tumor activity. ABNOBA GmbH, a Germany-based pharmaceutical company with a research-driven approach, has pioneered the development of standardized mistletoe extracts. ABNOBA India is bringing this science-backed natural therapy to Indian healthcare settings.
The therapeutic effects of mistletoe are primarily attributed to its bioactive compounds, including lectins, viscotoxins, polysaccharides, and flavonoids. Lectins, in particular, play a critical role—they bind to the surface of cancer cells, triggering apoptosis (programmed cell death). Simultaneously, these compounds activate immune cells such as macrophages, natural killer cells, and T-cells, enhancing the body's ability to recognize and fight malignant cells.
Mistletoe also helps in regulating the production of cytokines, the signaling proteins of the immune system, which improves immune balance. Furthermore, it has been observed to improve the overall well-being of patients by reducing treatment-related side effects such as fatigue, nausea, and loss of appetite.
Administered through subcutaneous injection, mistletoe therapy is tailored to individual patient needs. The dose and extract type vary depending on the type and stage of cancer, as well as patient tolerance.
ABNOBA’s focus on clinical research and product quality ensures that mistletoe therapy remains a reliable and safe complementary option in cancer treatment. As interest in integrative oncology grows, understanding the mechanism behind mistletoe therapy offers hope for improved patient outcomes.
